Barr J, Lushkov G, Strauss S, Gurevitch S, Lahat E, Bistritzer T, Klin B, Eshel G
Department of Pediatric Intensive Care, Assaf Harofeh Medical Center, Zerifin, Israel.
Thorax. 1996 Jan;51(1):82-6. doi: 10.1136/thx.51.1.82.
Peritoneal ventilation has been shown to be effective in achieving extrapulmonary oxygenation and carbon dioxide elimination in an animal model of severe adult respiratory distress syndrome (ARDS). Cisapride is a "prokinetic" agent (increases gastric emptying), that may increase the splanchnic circulation and thus favourably affect gas exchange in peritoneal ventilation.
Using Doppler ultrasound the effect of cisapride on the portal venous circulation was examined in eight spontaneously breathing rabbits and the effect of cisapride on gas exchange in five rabbits spontaneously breathing room air was compared with that of a control group who did not receive cisapride. Its effect on gas exchange in five rabbits with ARDS being treated with mechanical lung and peritoneal ventilation was compared with that of a control group, and its effect on gas exchange in five rabbits with ARDS treated with conventional ventilation was also compared with that of a control group.
Enteral administration of cisapride increased portal venous blood velocity, as measured ultrasonographically, by a mean of 188% one hour after receiving the drug. In rabbits with ARDS being treated with both peritoneal ventilation and mechanical ventilation to the lungs, those receiving cisapride had arterial oxygen tensions 1.5-3 times that of controls. Cisapride had no effect on arterial blood gas tensions in rabbits who were spontaneously breathing room air, nor in rabbits with ARDS who received only conventional mechanical lung ventilation.
Cisapride increases arterial oxygenation in rabbits with severe ARDS treated with peritoneal ventilation, probably due to its ability to increase splanchnic circulation. It should be considered as an adjuvant medication to peritoneal ventilation.
在严重成人呼吸窘迫综合征(ARDS)动物模型中,腹膜通气已被证明在实现肺外氧合和二氧化碳清除方面是有效的。西沙必利是一种“促动力”药物(可增加胃排空),可能会增加内脏循环,从而对腹膜通气中的气体交换产生有利影响。
使用多普勒超声检查了西沙必利对8只自主呼吸兔门静脉循环的影响,并将5只自主呼吸空气的兔西沙必利对气体交换的影响与未接受西沙必利的对照组进行了比较。将其对5只接受机械通气和腹膜通气治疗的ARDS兔气体交换的影响与对照组进行了比较,还将其对5只接受传统通气治疗的ARDS兔气体交换的影响与对照组进行了比较。
经超声测量,西沙必利肠内给药后1小时,门静脉血流速度平均增加188%。在同时接受腹膜通气和肺机械通气治疗的ARDS兔中,接受西沙必利的兔动脉血氧张力是对照组的1.5至3倍。西沙必利对自主呼吸空气的兔以及仅接受传统肺机械通气的ARDS兔的动脉血气张力没有影响。
西沙必利可增加接受腹膜通气治疗的重度ARDS兔的动脉氧合,可能是由于其增加内脏循环的能力。应将其视为腹膜通气的辅助药物。